Applications invited from scientists for LBD Biomarker Research Award

NewsGuard 100/100 Score

The Alzheimer's Drug Discovery Foundation (ADDF) and the Lewy Body Dementia Association (LBDA) invite scientists from the biotechnology industry and academia worldwide to apply for a new collaborative research grant award entitled Lewy Body Dementia Biomarker Research Award. The goal of the program is to catalyze the discovery of innovative biomarkers that aid in early diagnosis, detection and disease monitoring of Lewy body dementias.

Lewy body dementias (LBD) are the second most common form of degenerative dementia in the elderly, affecting an estimated 1.3 million people in the United States. Yet many individuals who have LBD are misdiagnosed, most commonly with Alzheimer's or Parkinson's diseases. Developing effective biomarkers is key to helping to correctly diagnose the disease, monitor disease progression and develop effective new drugs to treat, prevent and cure LBD.

The total pool of grant funds available for fiscal year 2009 is $100,000. Applications may be submitted by non-profit academic institutions and for-profit public and private biotechnology companies.

Applications are available at www.alzdiscovery.org. The submission deadline date is November 1, 2009. Applications will be reviewed by an independent Scientific Review Committee convened by ADDF and LBDA and comprised of leading experts in the neurodegenerative disease drug discovery and development research field and biotechnology investment community. Funding will be announced in spring 2010.

Source: http://www.alzdiscovery.org

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer